^
Association details:
| Biomarker: | CCR4 overexpression |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + tivumecirnon (FLX475) (CCR4 receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Title:
RAPT THERAPEUTICS REPORTS POSITIVE INITIAL DATA FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF FLX475 IN MULTIPLE CANCER INDICATIONS
Published date:
11/16/2020
Excerpt:
Of the 10 evaluable patients with NPC treated with FLX475 monotherapy, seven of 10 (7/10) patients exhibited stable disease as best response.
